Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	3.99	4.65	2.86	2.02	2.88
Short-Term Investments	14.17	10.68	9.78	11.77	31.93
Cash & Short-Term Investments	18.16	15.33	12.64	13.79	34.82
Cash Growth	18.43%	21.27%	-8.29%	-60.41%	-31.58%
Other Receivables	0.35	0.67	0.48	0.83	1.13
Total Trade Receivables	0.35	0.67	0.48	0.83	1.13
Other Current Assets	0.12	0.12	0.12	0.11	0.11
Total Current Assets	18.63	16.12	13.24	14.72	36.05
Net Property, Plant & Equipment	-	-	0.13	0.34	0.55
Long-Term Investments	-	2.12	3.27	1.5	-
Other Long-Term Assets	-	0.26	-	-	-
Total Assets	18.63	18.5	16.63	16.56	36.61
Accounts Payable	2	1.31	1.88	2.56	4.87
Accrued Expenses	0.84	0.87	0.87	0.53	1.01
Total Current Liabilities	2.85	2.17	2.75	3.09	5.88
Total Liabilities	2.85	2.17	2.75	3.09	5.88
Common Stock	3.41	0.74	0.21	0.07	0.07
Additional Paid-in Capital	223.46	216.47	207.08	200.14	198.77
Accumulated Other Comprehensive Income	-0.3	-0.42	-0.45	-0.75	-0.17
Retained Earnings	-210.78	-200.47	-192.95	-186.04	-168.17
Shareholders' Equity	15.78	16.33	13.88	13.42	30.5
Total Liabilities & Equity	18.63	18.5	16.63	16.56	36.61
Net Cash (Debt)	18.16	15.33	12.64	13.79	34.82
Net Cash Growth	18.43%	21.27%	-8.29%	-60.41%	-31.58%
Net Cash Per Share	4.21	16.47	54.78	98.69	254.77
Book Value	15.78	16.33	13.88	13.42	30.5
Book Value Per Share	3.66	17.54	60.14	96.10	223.17
Tangible Book Value	15.78	16.33	13.88	13.42	30.5
Tangible Book Value Per Share	3.66	17.54	60.14	96.10	223.17

Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q